Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
56. |
ECCT/20/06/04 | ANTICOV (01 COV) An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. Mbagathi Infectious Disease Hospital (Nairobi City county) 2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county) |
View |
57. |
ECCT/21/04/01 | FujiLAM Study Diagnostic performance of a novel lipoarabinomannan test (FujiLAM) to detect tuberculosis in HIV-positive patients in Kenya |
Principal Investigator(s) 1. Helena Huerga Site(s) in Kenya Homabay County Teaching and Referral Hospital |
View |
58. |
ECCT/18/01/01 | Mal 094 Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age. |
Principal Investigator(s) 1. Aaron Samuels 2. Simon Kariuki Site(s) in Kenya 1. Siaya County Referral hospital (Siaya county) 2. Ngiya Health Center (Siaya county) 3. Kogelo Health Center (Siaya county) 4. Tingwangi (Siaya county) 5. Mulaha (Siaya county) 6. Nyathengo (Siaya county) 7. Bal Olengo (Siaya county) |
View |
59. |
ECCT/16/04/01 | HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection HVTN 703/HPTN 081 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection |
Principal Investigator(s) 1. Dr. Victor Akelo Akelo Site(s) in Kenya KISUMU CRS |
View |
60. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |